Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Douglas Johnson

5 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCMD1564

11/23/2015

Acquisition and Research Use of Biospecimens in Cancer Patients

Other

VICCMEL12117

02/18/2013

A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY?) as First-Line Therapy

Treatment

ECOGMELS1404

12/01/2015

A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Treatment

VICCMEL1486

05/01/2015

A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients with Advanced Uveal Melanoma

Treatment

VICCMEL1457

01/19/2015

A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations